207 related articles for article (PubMed ID: 31340938)
1. Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort.
Dihge L; Vallon-Christersson J; Hegardt C; Saal LH; Häkkinen J; Larsson C; Ehinger A; Loman N; Malmberg M; Bendahl PO; Borg Å; Staaf J; Rydén L
Clin Cancer Res; 2019 Nov; 25(21):6368-6381. PubMed ID: 31340938
[TBL] [Abstract][Full Text] [Related]
2. Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.
Orsaria P; Caredda E; Genova F; Materazzo M; Capuano I; Vanni G; Granai AV; DE Majo A; Portarena I; Sileri P; Petrella G; Palombi L; Buonomo OC
Anticancer Res; 2018 Apr; 38(4):2109-2117. PubMed ID: 29599329
[TBL] [Abstract][Full Text] [Related]
3. Can a machine-learning model improve the prediction of nodal stage after a positive sentinel lymph node biopsy in breast cancer?
Madekivi V; Boström P; Karlsson A; Aaltonen R; Salminen E
Acta Oncol; 2020 Jun; 59(6):689-695. PubMed ID: 32148141
[No Abstract] [Full Text] [Related]
4. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
[TBL] [Abstract][Full Text] [Related]
5. Artificial neural network models to predict nodal status in clinically node-negative breast cancer.
Dihge L; Ohlsson M; Edén P; Bendahl PO; Rydén L
BMC Cancer; 2019 Jun; 19(1):610. PubMed ID: 31226956
[TBL] [Abstract][Full Text] [Related]
6. HER2 expression is a strong independent predictor of nodal metastasis in breast cancer.
Ahmed AR
J Egypt Natl Canc Inst; 2016 Dec; 28(4):219-227. PubMed ID: 27756653
[TBL] [Abstract][Full Text] [Related]
7. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of Clinicopathological Characteristics for Sentinel Lymph Node Metastasis in Early Breast Cancer.
Ding J; Jiang L; Wu W
Med Sci Monit; 2017 Aug; 23():4102-4108. PubMed ID: 28839123
[TBL] [Abstract][Full Text] [Related]
9. Nomograms for preoperative prediction of axillary nodal status in breast cancer.
Dihge L; Bendahl PO; Rydén L
Br J Surg; 2017 Oct; 104(11):1494-1505. PubMed ID: 28718896
[TBL] [Abstract][Full Text] [Related]
10. Predictors of non-sentinel lymph node metastasis in clinical early stage (cT1-2N0) breast cancer patients with 1-2 metastatic sentinel lymph nodes.
Lale A; Yur M; Özgül H; Alkurt EG; Yıldırım N; Aygen E; Bahadır Öz A; Arıkan TB
Asian J Surg; 2020 Apr; 43(4):538-549. PubMed ID: 31519397
[TBL] [Abstract][Full Text] [Related]
11. A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients.
van den Hoven I; van Klaveren D; Voogd AC; Vergouwe Y; Tjan-Heijnen V; Roumen RM
Clin Breast Cancer; 2016 Apr; 16(2):123-30. PubMed ID: 26602438
[TBL] [Abstract][Full Text] [Related]
12. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
[TBL] [Abstract][Full Text] [Related]
13. Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers.
Bonsang-Kitzis H; Mouttet-Boizat D; Guillot E; Feron JG; Fourchotte V; Alran S; Pierga JY; Cottu P; Lerebours F; Stevens D; Vincent-Salomon A; Sigal-Zafrani B; Campana F; Rouzier R; Reyal F
PLoS One; 2017; 12(2):e0169962. PubMed ID: 28241044
[TBL] [Abstract][Full Text] [Related]
14. Integrative 3' Untranslated Region-Based Model to Identify Patients with Low Risk of Axillary Lymph Node Metastasis in Operable Triple-Negative Breast Cancer.
Wang L; Hu X; Wang P; Shao ZM
Oncologist; 2019 Jan; 24(1):22-30. PubMed ID: 30082491
[TBL] [Abstract][Full Text] [Related]
15. A mathematical prediction model incorporating molecular subtype for risk of non-sentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients: a retrospective analysis and nomogram development.
Wang NN; Yang ZJ; Wang X; Chen LX; Zhao HM; Cao WF; Zhang B
Breast Cancer; 2018 Nov; 25(6):629-638. PubMed ID: 29696563
[TBL] [Abstract][Full Text] [Related]
16. Machine Learning-Based Epigenetic Classifiers for Axillary Staging of Patients with ER-Positive Early-Stage Breast Cancer.
Orozco JIJ; Le J; Ensenyat-Mendez M; Baker JL; Weidhaas J; Klomhaus A; Marzese DM; DiNome ML
Ann Surg Oncol; 2022 Oct; 29(10):6407-6414. PubMed ID: 35842534
[TBL] [Abstract][Full Text] [Related]
17. Role of number of sentinel nodes in predicting non-sentinel node metastasis in breast cancer.
Dong LF; Xu SY; Long JP; Wan F; Chen YD
J Int Med Res; 2018 Feb; 46(2):828-835. PubMed ID: 29441833
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
19. A N0 Predicting Model for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer Upstaged From Ductal Carcinoma in Situ.
Yoo TK; Kim SJ; Lee J; Lee SB; Lee SJ; Park HY; Park HK; Chae BJ; Eom YH; Kim HS; Song BJ
Clin Breast Cancer; 2020 Jun; 20(3):e281-e289. PubMed ID: 32147404
[TBL] [Abstract][Full Text] [Related]
20. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
